Results 261 to 270 of about 33,586 (335)
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
ABSTRACT Sirolimus is a third‐generation immunosuppressant with multiple efficacies, including antifungal, antitumor, and immunosuppressive properties. We conducted a pharmacokinetic study to determine the effect of berberine hydrochloride (BBR) on the pharmacokinetics of sirolimus in rats.
Yuanxia Yang+3 more
wiley +1 more source
Miniaturized click chemistry and direct screening facilitate the discovery of triazole piperazine SARS-CoV-2 Mpro inhibitors with improved metabolic stability. [PDF]
Gao S+9 more
europepmc +1 more source
ABSTRACT Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐lowering drugs such as statins.
Hang Yang+9 more
wiley +1 more source
StaufenC facilitates utilization of the ERAD pathway to transport dsRNA through the endoplasmic reticulum to the cytosol. [PDF]
Koo J, Palli SR.
europepmc +1 more source
ABSTRACT Adult patients with anaplastic lymphoma kinase positive (ALK+) advanced non–small‐cell lung cancer (NSCLC) are treated with 600 mg alectinib twice daily (BID) as first‐line treatment. ALK positive solid and central nervous system (CNS) tumors are described in the pediatric population, with limited clinical data due to the rarity of the disease
Tamara van Donge+6 more
wiley +1 more source
Structure-Based Optimization of Selective and Brain Penetrant CK1δ Inhibitors for the Treatment of Circadian Disruptions. [PDF]
McCarver S+14 more
europepmc +1 more source
ABSTRACT The orally inhaled route of administration for respiratory indications can maximize drug exposure to the site of action (lung) to increase efficacy while minimizing systemic exposure to achieve an improved safety profile. However, due to the difficulty of taking samples from different regions of the human lung, often only systemic ...
Rui Zhu+12 more
wiley +1 more source